Trial Watch: experimental TLR7/TLR8 agonists for oncological indications

被引：98

作者：

Frega, Giorgio ^{[1
,2
,3
]}

Wu, Qi ^{[1
,2
]}

Le Naour, Julie ^{[1
,2
]}

Vacchelli, Erika ^{[1
,2
]}

Galluzzi, Lorenzo ^{[4
,5
,6
,7
,8
]}

Kroemer, Guido ^{[1
,2
,9
,10
,11
]}

Kepp, Oliver ^{[1
,2
]}

机构：

[1] Sorbonne Univ, Univ Paris, Ctr Rech Cordeliers, INSERM UMR1138,Equipe Labellisee Ligue Canc, Paris, France

[2] Gustave Roussy, Metab & Cell Biol Platforms, Villejuif, France

[3] Univ Bologna, St Orsola Malpighi Hosp, Dept Expt Diagnost & Specialty Med, Bologna, Italy

[4] Weill Cornell Med Coll, Dept Radiat Oncol, New York, NY USA

[5] Sandra & Edward Meyer Canc Ctr, New York, NY USA

[6] Caryl & Israel Englander Inst Precis Med, New York, NY USA

[7] Yale Sch Med, Dept Dermatol, New Haven, CT USA

[8] Univ Paris, Paris, France

[9] Chinese Acad Med Sci, Suzhou Inst Syst Med, Suzhou, Peoples R China

[10] Hop Europeen Georges Pompidou, AP HP, Pole Biol, Paris, France

[11] Karolinska Univ Hosp, Dept Womens & Childrens Hlth, Karolinska Inst, Stockholm, Sweden

来源：

ONCOIMMUNOLOGY | 2020年 / 9卷 / 01期

基金：

欧盟地平线“2020”;

关键词：

Cancer immunotherapy; CGAS; danger signaling; immune checkpoint blockers; immunogenic cell death; type I interferon; TOLL-LIKE RECEPTORS; INNATE IMMUNE-RESPONSES; IMMUNOGENIC CELL-DEATH; DENDRITIC CELLS; NUCLEIC-ACIDS; LUNG-CANCER; CLINICAL-OUTCOMES; I INTERFERONS; NON-SELF; 852A;

D O I：

10.1080/2162402X.2020.1796002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Resiquimod (R848) and motolimod (VTX-2337) are second-generation experimental derivatives of imiquimod, an imidazoquinoline with immunostimulatory properties originally approved by the US Food and Drug Administration for the topical treatment of actinic keratosis and genital warts more than 20 years ago. Both resiquimod and motolimod operate as agonists of Toll-like receptor 7 (TLR7) and/or TLR8, in thus far delivering adjuvant-like signals to antigen-presenting cells (APCs). In line with such an activity, these compounds are currently investigated as immunostimulatory agents for the treatment of various malignancies, especially in combination with peptide-based, dendritic cell-based, cancer cell lysate-based, or DNA-based vaccines. Here, we summarize preclinical and clinical evidence recently collected to support the development of resiquimod and motolimod and other TLR7/TLR8 agonists as anticancer agents.

引用

页数：10

共 146 条

[1]

Ackerman S.E., 2019, Cancer Res, V79, P1559, DOI [10.1158/1538-7445.AM2019-1559, DOI 10.1158/1538-7445.AM2019-1559]

[2]

RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer [J].